Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Introduction The efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy. Case presentation A 75‐year‐old man initially d...

全面介紹

書目詳細資料

Principais autores:	Riko Ikeda, Yoh Matsuoka, Masaharu Inoue, Ayataka Ishikawa, Kiwamu Akagi, Yukio Kageyama
格式:	Artigo
語言:	Inglês
出版:	Wiley 2024-03-01
叢編:	IJU Case Reports
主題:	BRCA2 castration‐resistant neuroendocrine tumor poly(ADP‐ribose) polymerase inhibitors prostate cancer
在線閱讀:	https://doi.org/10.1002/iju5.12679
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!